Medexis S Translating Basic Science into Value 5
Medexis SΑ Translating Basic Science into Value 5 th Venture Capital Forum Athens, 16 -17 June 2004 Member of Group
Medexis Presentation: Overview ØCorporate Profile & Mission ØThe Gerolymatos Group ØStructure & Organization ØCorporate Strategy ØResearch & Development ØProject Portfolio ØConclusions Member of Group
Corporate Profile & Mission Ø Incorporated in 2002, fully owned by the Gerolymatos Group of Companies. Ø Biotechnology Venture of the Group focusing on Research & Development activities in Greece. Ø Medexis’s strategic objective is to identify, develop and commercialize novel therapeutic molecules and technologies for the treatment of critical diseases in human patients. Member of Group
The Gerolymatos Group Ø Active in the Health & Beauty Business for more than 80 years. Ø Product range includes: Pharmaceuticals, OTC, Diagnostics, Veterinary, Cosmetics, and Consumer products. Ø Custom manufacturing & distribution for third parties. Ø Warehousing space 13, 000 m 2. Ø Three production plants for pharmaceuticals & cosmetics. Member of Group
The Gerolymatos Group Ø Offices in Athens, Kryoneri and Salonica. Ø Exports to more than 20 countries. Ø Subsidiaries: 6 in Greece + 6 Abroad. Ø >850 Employees. Ø 2003 Sales: € 165. 4 million. Member of Group
Structure & Organization Ø Located in Kryoneri, Corporate Headquarters Ø Utilizes Corporate resources Ø Management & Marketing experience of the Group Member of Group
Structure & Organization Ø Extensive network of scientific advisors Ø Intellectual property experts Ø 100% of the budget devoted to R & D activities ØThe only company investing in Greek biotech research Scientific Advisory Board • • • Prof. Christos Stournaras (Medical School, University of Crete) Dr. Nikos Bakopoulos (Chief Executive Officer, Aton Pharma Inc) Dr. George Pavlakis (Head of Retroviral Section, National Cancer Institute) Dr Aris Persidis (VP Research & Development, Upstate Inc) Dr Basil Theofanopoulos (General Manager, Gerolymatos Inc) Member of Group
Corporate Strategy Ø Medexis seeks, evaluates and selectively invests in early stage R & D projects with commercial potential that are being developed in Greek Academic Institutions with an aim to develop novel therapeutic treatments. Ø Areas of therapeutic interest include: • • Cancer CNS Diseases Infectious Diseases Inflammation & Wound healing Member of Group
Corporate Strategy ØStrategic contacts and alliances with prominent Greek Research Institutes allow for identification of interesting IP ØAssignment of the commercial exploitation of the invention in exchange to royalties on future profits (in-licensing) ØR & D funding according to specific scientific milestones ØDevelopment of IP portfolio ØDevelopment of product candidates from an early pre-clinical to a late-preclinical stage (IND) or phase I before partnering with a strategic ally (out-licensing) Member of Group
Research & Development In -Licensing Out -Licensing Discovery Phase I 0 Full Development Drug Evaluation 5 Idea Phase III Phase II 10 15 Drug 12 -15 Years ØDevelop therapeutic molecules from an early pre-clinical to a late pre-clinical stage (IND) or phase I. ØOut – license project to a strategic partner(s) in exchange of cash down payments, milestone payments and royalties. Member of Group
Research & Development In -Licensing Out -Licensing Discovery Phase I 0 Phase III Phase II 5 Idea Ø Ø Full Development Drug Evaluation 10 Drug 12 -15 Years Scientific Innovation & Excellence IP Evaluation and Patentability Commercial Potential/Business Risk Regulatory Member of 15 Group
Project Portfolio Gerolab Project • Pharmaceutical formulations comprising labdanes for the treatment of tumors and leukemia. Cast. BSA Project • Steroid-protein conjugates for the treatment of tumors and hematological malignancies. Angiomed Project • Novel angiogenic molecules for the treatment of cancer and ophthalmic disorders. Member of Group
Project Portfolio Gerolab Project • R & D Status: • Patent Status: Proof-of-concept, colon cancer GR 1003509, US 6, 652, 877, AU 773462 PCT/GR 00/00033 (WO 01/34116) pending in EPO, Canada, Japan Cast. BSA Project • R & D Status: • Patent Status: Proof-of-concept, prostate cancer GR 1004274 PCT/IB 03/02785 (WO 04/06966) pending for 122 countries Angiomed Project • R & D Status: • Patent Status: Proof-of-concept, neuroblastomas GR 20030100319, GR 20030100362, pending US 60/493. 975, US 60/502. 047, pending Member of Group
Project Portfolio Helixplast ØMedical Device of class IIb based on Helixderm®, a pharmaceutical product of herbal origin approved by EOF for wound healing. ØCE Mark ØLaunch in Greece & Europe within 2005 Member of Group
Conclusions ØMedexis focuses on early stage biotechnology projects aiming at the development of novel therapeutic applications. ØMedexis promotes technology transfer from the Academic Institutions to the industry financing Research & Development and developing the product IP portfolio. ØMedexis’s strategic goal is to develop product candidates to a late preclinical stage (IND) or phase I and collaborate with a strategic partner for further development/clinical testing of the products. ØMedexis’s portfolio consists of three anti-cancer projects currently at the proof-of-concept stage in animal models of cancer. Member of Group
Medexis SΑ Translating Basic Science into Value 5 th Venture Capital Forum Athens, 16 -17 June 2004 Kostantinos Alevizopoulos Ph. D. Medexis SA contact@medexis-biotech. com Member of Group
- Slides: 16